-
Ex-BioMarin CEO Bienaimé re-emerges at Owkin
26 Mar 2024 12:14 GMT
… stint as chief executive of BioMarin, Jean-Jacques Bienaimé, has been … biomarkers and therapeutic targets in cancer, adding a new programme in … .
During his tenure at BioMarin, Bienaimé steered BioMarin from a company with …
-
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
22 Jan 2024 22:59 GMT
… LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics … gain, fluid retention, cancer risk, and susceptibility to … LLC, Madrigal Pharmaceuticals, Inc., BioMarin Pharmaceutical, GlaxoSmithKline, Zydus Therapeutics …
-
BioMarin appeases an activist
21 Dec 2023 15:49 GMT
… , the new CEO of BioMarin Pharmaceutical, had an unenviable … that attract activist pressure, BioMarin actually makes money, and … antibody-drug conjugate, a cancer-treating technology with a long … treatment for lung and other cancers. The deal, worth up …
-
STAT+: Pharmalittle: FDA rejects Merck cough medicine; Sanofi abandons an ADC for lung cancer
21 Dec 2023 15:49 GMT
Good morning, everyone. Damian Garde here, filling in for Ed Silverman in a week customarily devoted to deciding just which tasks one can get away with putting off until next year. Here’s hoping you’re firmly on the downslope of doing actual work for the …
-
BioMarin Announces Governance Enhancements and Value Creation Initiatives
21 Dec 2023 10:20 GMT
… training at the Fred Hutchinson Cancer Research Center in the Pediatric … the boards of The American Cancer Society of Eastern New England … the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, our …
-
BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge
08 Nov 2023 15:44 GMT
… tools to target only cancer cells and spare healthy … of relative weakness for BioMarin. The company recently scaled … that attract activist pressure, BioMarin actually makes money, and … the-shelf cell therapies for cancer and autoimmune diseases, Endpoints
• …
-
BioMarin, Twist Bioscience win CLS Pantheon Awards
03 Nov 2023 19:39 GMT
… Biotechnology Innovation Organization (BIO) members – BioMarin and Twist Bioscience – were recognized … and Leadership Award, respectively.
BioMarin focuses on developing treatments for … and enable other discoveries for cancer and infectious diseases.
CLS CEO …
-
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2023 Earnings Call Transcript
02 Nov 2023 21:21 GMT
… about the business prospects of BioMarin Pharmaceutical, Inc., including expectations … products in therapeutics areas, including cancer and hemophilia. Serving as CEO … penetration of indicated patients in BioMarin’s commercial footprint, highlighting the …
-
FDA hands down label expansions for Genentech and BioMarin drugs in cancer, dwarfism
23 Oct 2023 18:52 GMT
Even younger pediatric patients with solid tumors or short-limbed dwarfism will now have access to treatment after the FDA approved label expansions late Friday for drugs by Genentech and BioMarin.
California-based BioMarin said that the …
-
FDA Action Alert: Merck, Ardelyx, BioMarin and More
16 Oct 2023 06:34 GMT
… one for a blockbuster cancer treatment and another for … IIIB non-small cell lung cancer (NSCLC) before and … dermatology unit Ortho Dermatologics.
BioMarin Proposes Voxzogo for Younger … anticipated FDA decisions involves BioMarin’s Voxzogo (vosoritide), …